- Home
- SEZL vs TLX Comparison
SEZL vs TLX Comparison
Compare SEZL & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEZL
- TLX
- Stock Information
- Founded
- SEZL 2016
- TLX 2015
- Country
- SEZL United States
- TLX Australia
- Employees
- SEZL N/A
- TLX N/A
- Industry
- SEZL Diversified Financial Services
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- SEZL Finance
- TLX Health Care
- Exchange
- SEZL Nasdaq
- TLX Nasdaq
- Market Cap
- SEZL 3.0B
- TLX 3.2B
- IPO Year
- SEZL N/A
- TLX N/A
- Fundamental
- Price
- SEZL $90.13
- TLX $9.18
- Analyst Decision
- SEZL Buy
- TLX Strong Buy
- Analyst Count
- SEZL 4
- TLX 3
- Target Price
- SEZL $113.75
- TLX $21.33
- AVG Volume (30 Days)
- SEZL 834.3K
- TLX 257.4K
- Earning Date
- SEZL 11-06-2025
- TLX 01-01-0001
- Dividend Yield
- SEZL N/A
- TLX N/A
- EPS Growth
- SEZL 146.46
- TLX N/A
- EPS
- SEZL 2.93
- TLX 0.04
- Revenue
- SEZL $371,794,890.00
- TLX $664,225,558.00
- Revenue This Year
- SEZL $66.31
- TLX N/A
- Revenue Next Year
- SEZL $28.42
- TLX N/A
- P/E Ratio
- SEZL $30.16
- TLX $220.22
- Revenue Growth
- SEZL 92.95
- TLX 55.35
- 52 Week Low
- SEZL $23.41
- TLX $8.93
- 52 Week High
- SEZL $186.74
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- SEZL 41.83
- TLX 34.46
- Support Level
- SEZL $86.51
- TLX $9.14
- Resistance Level
- SEZL $91.29
- TLX $9.53
- Average True Range (ATR)
- SEZL 4.86
- TLX 0.19
- MACD
- SEZL 1.76
- TLX 0.10
- Stochastic Oscillator
- SEZL 49.34
- TLX 30.49
About SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, the majority of which derives revenue from payment processing platform in North America.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.